Recent Updates
Recently added Catalysts

Melatonin- Active light ttherapy

Phase 2

Idiopathic Hypersomnia | Small molecule | Neurology |Pulmonx Corporation|Last Updated: Aug 20, 2026

Target and mechanism

ModalitySmall molecule

Also known as - Melatonin - Active light ttherapy

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment72

FDA Designations

No designations recorded

Clinical trial landscape

Melatonin- Active light ttherapy · 1 trial · 1 indication

Phase 2 1
NCT06252571a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -TrialIdiopathic Hypersomnia
RECRUITING72 Analytics
PHASE2RECRUITING
a Chronobiological Treatment Combining Evening Melatonin and Morning Light Therapy in Idiopathic Hypersomnia: a Prospective, Double Bind, Randomized, Placebo-controlled -Trial
Idiopathic HypersomniaUnlock trial analytics

Study Endpoints

Primary Endpoints

Idiopathic Hypersomnia Severity Severity Scale (IHSS)
At Day 14 and day 45

The Idiopathic Hypersomnia Severity Severity Scale is a self-administered questionnaire that was designed specifically to quantify HI symptoms the minimum value is 0 and the maximum values 50 means a worse outcome.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Active therapyEXPERIMENTALActive therapy combining evening melatonin + morning active light over 6 weeks
Placebo therapyPLACEBO_COMPARATORplacebo therapy combining evening melatonin placebo + morning placebo light over 6 weeks.

Interventions

NameTypeDescription
- Melatonin - Active light ttherapyCOMBINATION_PRODUCT1 tablet per day, in the evening + morning light therapy over 6 weeks
- Placebo drug - Placebo light therapyCOMBINATION_PRODUCT1 tablet per day in the evening + morning placebo light therapy
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 40 Years
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion criteria: * Male or female patient * Age ≥ 18 and ≤ 40 years at signature of informed consent form * Diagnosed with Idiopathic hypersomnia in a reference/competence center of hypersomnia rare disease network according to ICSD-3 criteria (International classification of sleep disorders) wi...

Countries:France
Unlock Eligibility Criteria